Potential molecular targeting of splice variants for cancer treatment

Indian Journal of Experimental Biology

Volumn 49, Issue 11, 2011, Pages 836-839

  Blair, Christopher A ^a   Zi, Xiaolin ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer therapeutics; Expressed sequence tags; Osteopontin c; SiRNA; Tumour specific splice variants

Indexed keywords

ISOPROTEIN; OSTEOPONTIN; SMALL INTERFERING RNA;

ALTERNATIVE RNA SPLICING; DISEASE COURSE; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; REVIEW;

ALTERNATIVE SPLICING; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; OSTEOPONTIN; PROTEIN ISOFORMS; RNA, SMALL INTERFERING;

EID: 80355141485     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Black D L, Protein diversity from alternative splicing: a challenge for bioinformatics and post-genome biology, Cell, 103 (2000) 367.
2. Graveley B R, Alternative splicing: increasing diversity in the proteomic world, Trends Genet, 17 (2001) 100.
3. Sarquis M S, Agrawal S, Shen L, Pilarski R, Zhou X P & Eng C, Distinct expression profiles for PTEN transcript and its splice variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome, Am J Hum Genet, 79 (2006) 23.
4. Futreal P A, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N & Stratton M R, A census of human cancer genes, Nat Rev Cancer, 4 (2004) 177.
5. Brentani H, Caballero O L Camargo A A, et al., The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags, Proc Natl Acad Sci U S A, 100 (2003) 13418.
6. Xu Q & Lee C: Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences, Nucleic Acids Res, 31 (2003) 5635.
7. Gupta S, Zink D, Korn B, Vingron M & Haas S A, Strengths and weaknesses of EST-based prediction of tissue-specific alternative splicing, BMC Genomics, 5 (2004) 72.
8. Tilli T M, Franco V F, Robbs B K, Wanderley J L, da Silva F R, de Mello K D, Viola J P, Weber G F & Gimba E R, Osteopontin-c splicing isoform contributes to ovarian cancer progression, Mol Cancer Res, 9 (2011) 280.
9. Vivas-Mejia P E, Rodriguez-Aguayo C, Han H, Shahzad M M K, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood A K & Lopez-Berestein G, Silencing survivin splice variant 2B Leads to antitumor activity in taxane-resistant ovarian cancer, Clin Cancer Res, 17 (2011) 3716.
10. Dietel M, Häfner N, Jansen L, Dürst M & Runnebaum IB, Novel splice variant CAR 4/6 of the coxsackie adenovirus receptor is differentially expressed in cervical carcinogenesis, J Mol Med, 89 (2011) 621.
11. Taplin M E, Drug Insight: role of the androgen receptor in the development and progression of prostate cancer, Nat Clin Pract Oncol, 4 (2007) 236.
12. Chen Y, Clegg N J & Scher H I, Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target, Lancet Oncol, 10 (2009) 981.
13. Dehm S M, Schmidt L J, Heemers H V, Vessella R L & Tindall D J, Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance, Cancer Res, 68 (2008) 5469.
14. Guo Z, Yang X, Sun F, Jiang R, Linn D E, Chen H, Kong X, Melamed J, Tepper C G, Kung H, Brodie A M H, Edwards J & Qui Y, A novel androgen receptor splice variant is upregulated during prostate cancer progression and promotes androgen depletion-resistant growth, Cancer Res, 69 (2009) 2305.
15. Hu R, Dunn T A, Wei S, Isharwal S, Veltri R W, Humphreys E, Han M, Partin A W, Vessella R L, Isaacs W B, Bova G S & Luo J, Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer, Cancer Res, 69 (2009) 16.
16. Sun S, Sprenger C C, Vessella R L, Haugk K, Soriano K, Mostaghel E A, Page S T, Coleman I M, Nguyen H M, Sun H, Nelson P S & Plymate S R, Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant, J Clin Invest, 120 (2010) 2715.
17. Marcias G, Erdmann E, Lapouge G, Siebert C, Barthélémy P, Duclos B, Bergerat J P, Céraline J & Kurtz J E, Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line, Hum Mutat, 31 (2010) 74.
18. Watson P A, Chen Y F, Balbas M D, Wongvipat J, Socci N D, Viale A, Kim K & Sawyers C L, Constitutively active androgen receptor splice variants expressed in castrationresistant prostate cancer require full-length androgen receptor, Proc Natl Acad Sci U S A, 107 (2010) 16759.
19. Hammond S M & Wood M J A, Genetic therapies for RNA mis-splicing diseases. Trends Genet, 27 (2011) 196.
20. Lu Q, Yokota T, Takeda S, Garcia L, Muntoni F & Partridge T, The status of exon skipping as a therapeutic approach to Duchenne muscular dystrophy, Mol Ther, 19 (2011) 9.
21. Aartsma-Rus A & van Ommen G B, Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications. RNA, 13 (2007) 1609.
22. Heemskerk H, de Winter C L, van Ommen G J, van Deutekom J C & Aartsma-Rus A, Development of antisensemediated exon skipping as a treatment for Duchenne muscular dystrophy, Ann NY Acad Sci, 1175 (2009) 71.
23. Goemans N M, Tulinius M, van den Akker J T, Burm B E, Ekhart P F, Heuvelmans N, Holling T, Janson A A, Platenburg G J, Sipkens J A, Sitsen J M, Aartsma-Rus A, van Ommen G J, Buyse G, Darin N, Ver-schuuren J J, Campion G V, de Kimpe S J & van Deutekom J C, Systemic administration of PRO051 in Duchenne's muscular dystrophy, N Engl J Med, 364 (2011) 1513.
24. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyannopoulos P, Garralda M E, Rutherford M, McCulley C, Popplewell L, Graham I R, Dickson G, Wood M J, Wells D J, Wilton S D, Kole R, Straub V, Bushby K, Sewry C, Morgan J E & Muntoni F, Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study, Lancet Neurol, 8 (2009) 918.
25. Carrasco R A, Stamm N B, Marcusson E, Sandusky G, Iversen P & Patel B K R, Antisense Inhibition of Survivin Expression as a Cancer Therapeutic, Mol Cancer Ther, 10 (2011) 221.
26. Fukuda S & Pelus L M, Regulation of the inhibitor-ofapoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis, Blood, 98 (2001) 2091.
27. Bauman J A, Li S D, Yang A, Huang L, Kole R, Anti-tumor activity of splice-switching oligonucleotides, Nucl Acids Res, 38 (2010) 8348.
28. Li Y, Alsagabi M, Fan D, Bova G S, Tewfik A H, Dehm S M, Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression, Cancer Res, 71 (2011) 2108.
29. Mashima T, Okabe S & Seimiya H, Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth, Mol Pharmacol, 78 (2010) 846.